John Leonard, M.D.
Dr. Leonard is President and CEO of Intellia Therapeutics, where he directs the research and development effort to turn CRISPR/Cas9 technology into a therapeutic reality. Previously, he served as the global head of Pharmaceutical R&D at Abbott Laboratories, where his groundbreaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. In addition to serving on the Board of Directors of 3T and Intellia, Dr. Leonard serves on the boards of IQVIA and IFM Therapeutics. He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in internal medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.
